Amyloid beta peptide (Aβ) is produced through the proteolytic processing of a
transmembrane protein, amyloid precursor protein (APP), by β-and γ-secretases. Aβ …

Currently, acetylcholinesterase (AChE) inhibitors are the most promising class of drugs for
the treatment of Alzheimer's disease (AD). Galantamine is a reversible, competitive, tertiary …

Social development, better living conditions and medical advances lead to the fact that more
people have the opportunity to live longer than in the past. The aging population is a …

Alzheimer's disease (AD), the most common form of dementia, is a progressive and
multifactorial neurodegenerative disorder whose primary causes are mostly unknown. Due …

BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disease that
places substantial burdens on those who provide support for family members with declining …

Currently available therapies for the treatment of Alzheimer's disease (AD) consist of
cholinesterase inhibitors (ChEIs), such as donepezil, and the N-methyl-D-aspartate receptor …

Objectives: To analyze the relationship between comorbid conditions and costs for patients
with AD and related dementias (ADRD) in a Medicare managed care organization (MCO) …

Background: The number of patients with Alzheimer's disease (AD) and related dementia
treated in managed care organizations (MCOs) is increasing, and this trend is expected to …

Alzheimer's disease is a devastating chronic disease that significantly increases healthcare
costs and affects the quality of life (QoL) of the afflicted patients and their caregivers …

Background: Alzheimer's disease (AD), a progressive degenerative disorder of the brain, is
the most common cause of cognitive impairment in the elderly. The pharmacotherapy of AD …